Charles River Laboratories and Â鶹Æƽâ°æ today announced results of a successful collaboration
Read next in 'Latest news'
- Enrollment completed for our Phase 2 clinical trial in Alport syndrome
- The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
- The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
Latest Press Release 